Дело C-513/16: EMA/PTC Therapeutics International, Определение от 1 март 2017 г.

Текст

... 6/2004 — Regulation (EC) No 141/2000 — Regulation (EC) No 507/2006 — Documents held by the European Medicines Agency (EMA) submitted in connection with an application for marketing authorisation for an orphan medicinal product — Decision to grant a third party access to documents — Suspension of the operation of that decision — Prima facie case — Urgency — Balancing of interests)

In Case C‑513/16 P(R),

APPEAL under the second paragraph of Article 57 of the Statute of the Court of Justice of the European Union, brought on 29 September 2016,

European Medicines Agency (EMA), represented by S. Marino, A. Spina, T. Jabłoński, A. Rusanov and N. Rampal Olmedo, acting as Agents,

appellant,

the other parties to the proceedings being:

PTC Therapeutics International Ltd, established in Dublin (Ireland), represented by M. Demetriou QC, C. Thomas, Barrister, and by G. Castle, B. Kelly and H. Billson, Solicitors,

applicant at first instance,

European Confederation of Pharmaceutical Entrepreneurs (Eucope), established in Brussels (Belgium), represented by D. Scannell, Barrister, and S. Cowlishaw, Solicitor,

intervener at first instance,

THE VICE-PRESIDENT OF THE COURT OF JUSTICE,

after hearing the Advocate General, M. Wathelet,

makes the following

Order

1. By its appeal, the European Medicines Agency (EMA) seeks to have set aside the order of the President of the General Court of the European Union of 20 July 2016, PTC Therapeutics International v EMA (T‑718/15 R, not published, ‘the order under appeal’, EU:T:2016:425), by which the latter ordered suspension of the operation of Decision EMA/722323/2015 of the ...